SCNI News and Press, Scanner Technologies Corp From 12/29/23

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products and provision of boutique CDMO (“CDMO”) services, has entered a d...

2023-12-29 09:30:29 ET More on Scinai Immunotherapeutics Scinai Immunotherapeutics regains compliance with stockholders' equity rule Seeking Alpha’s Quant Rating on Scinai Immunotherapeutics Historical earnings data for Scinai Immunotherapeutics Financ...

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds PR Newswire JERUSALEM , Dec. 29, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused both on developme...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on the development of both inflammation and immunology. During the webinar, SCNI CEO Amir Reichman will present an overview of the company’s performance throughout the year 2023, along with a discussio...

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9 PR Newswire JERUSALEM , Dec. 27, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunolo...

A recent paper that was published in the  “Nature"  journal has redefined rheumatoid arthritis (RA) and potentially opened the door to the development of targeted therapies. Researchers analyzed tissue collected from the synovial joints of almost 80 people diagnosed with moder...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, has announced successful preclinical trial results of its innovative anti ...

Scinai Announces Promising Results in a Psoriatic Human Skin Model PR Newswire JERUSALEM , Dec. 12, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology biologica...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, is announcing the publication of a peer-reviewed article regarding NanoAbs. Th...

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug PR Newswire Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases...